We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Next-generation RNA vaccines
- Dr. Anna Blakney
-
34. Harnessing the immune system for cancer therapy
- Dr. Raghav Sundar
-
35. Rac-enhanced CAR immunotherapy: RaceCAR
- Prof. Denise Montell
-
36. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1
- Prof. Kevin Harrington
-
37. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2
- Prof. Kevin Harrington
-
38. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
39. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
40. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
41. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
42. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
43. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
44. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
45. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
47. HCV resistance
- Prof. John Dillon
-
48. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
49. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
50. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
51. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
52. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
53. Cow’s milk allergy: the future
- Dr. Carina Venter
-
54. Cow's milk allergy: management
- Dr. Carina Venter
-
55. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
56. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
57. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
58. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
59. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
60. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
61. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
62. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
63. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
64. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
66. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
67. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
68. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
70. Huxley’s science fiction: ion channels in pain, pain resilience, and beyond
- Prof. Stephen Waxman
-
71. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
72. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
73. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
74. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
75. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
76. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
77. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
78. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
79. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
80. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
81. Peptide-drug conjugates as therapeutic modality in drug development 1
- Dr. Syed Faheem Askari Rizvi
-
82. Peptide-drug conjugates as therapeutic modality in drug development 2
- Dr. Syed Faheem Askari Rizvi
-
83. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
84. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
85. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
86. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
87. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
88. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
89. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
90. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
91. AI and big data in drug discovery
- Mr. Ed Addison
-
92. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
93. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
94. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
95. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
96. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
97. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
98. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
99. Diagnosis of tuberculosis and drug resistant tuberculosis 1
- Dr. Daniela Cirillo
-
100. Diagnosis of tuberculosis and drug resistant tuberculosis 2
- Dr. Daniela Cirillo
-
101. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
102. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
103. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
104. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
105. New drugs for asthma
- Prof. Peter Barnes
-
106. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
107. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Global report 2023
- The global burden of TB, latest estimates 2022
- TB incidence continues to increase globally
- Global recovery in reported number of people newly diagnosed with TB
- Narrowing the global gap
- Mycobacteria and M. tuberculosis complex (MTBC)
- Established knowledge: the bug and resistance
- END TB targets on diagnosis
- Diagnosis of pulmonary tuberculosis
- Evolution of TB diagnostics recommended by WHO
- 2024 New consolidated guidelines
- When is it recommended to use tNGS?
- WHO guidance on WGS/tNGS (1)
- WHO guidance on WGS/tNGS (2)
- WHO catalogue of DR mutations in MTBC
- Are smear microscopy culture and pDST still useful?
- Smear microscopy
- Culture based diagnosis
- Methods used for drugs sensitivity
- Do we still need pDST?
Topics Covered
- Global burden of TB
- M. tuberculosis complex (MTBC)
- Evolution of TB diagnostics
- 2024 new consolidated guidelines
- Targeted next generation sequencing (tNGS)
- WHO guidance on tNGS/WGS
- Phenotypic DST vs. genotypic DST
Links
Series:
Categories:
Therapeutic Areas:
External Links
- Slides 3-7- Global Tuberculosis Report 2023
- Slide 12-14- WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection
- Slide 12- Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance
- Slide 12- WHO launches new guidance on the use of targeted next-generation sequencing tests for the diagnosis of drug-resistant TB and a new sequencing portal
- Slide 12- Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis
- Slide 12- Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis
- Slide 15- Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance
- Slide 15- Guidance for the surveillance of drug resistance in tuberculosis
- Slide 15- The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide
- Slide 17- Clockwork
- Slide 22,31- WHO operational handbook on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection
- Slide 26- WHO consolidated guidelines on tuberculosis: module 4: treatment and care
- Slide 28- Consultation on breakpoint changes necessary in conjunction with introducing new definitions of S, I and R in the EUCAST breakpoint Table v 9.0.
- Slide 29- Antimicrobial susceptibility testing of Mycobacteria: EUCAST
- Slide 29- SOP for calibrating surrogate MIC methods for M. tuberculosis against the EUCAST reference MIC method
- Slide 30- BCCM/ITM Mycobacteria Collection
Talk Citation
Cirillo, D. (2025, July 31). Diagnosis of tuberculosis and drug resistant tuberculosis 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved August 30, 2025, from https://doi.org/10.69645/KLPI6285.Export Citation (RIS)
Publication History
- Published on July 31, 2025
Financial Disclosures
- There are no commercial/financial matters to disclose.
Diagnosis of tuberculosis and drug resistant tuberculosis 1
Published on July 31, 2025
29 min
A selection of talks on Immunology
Transcript
Please wait while the transcript is being prepared...
0:00
Good morning. My name
is Daniela Cirillo.
I work at the San Raffaele
Scientific Institute in Milano,
where I'm leading a WHO
collaborating center
in tuberculosis
laboratory strengthening.
The topic of today
is the diagnosis of
tuberculosis and
drug-resistant tuberculosis.
0:23
Briefly, my outline will
touch on the introduction
of tuberculosis,
the guidelines for the
diagnosis of tuberculosis
that have been very
recently issued by the WHO,
the role of WGS and the targeted
NGS, and the mechanism of
resistance with
particular attention to
the new drugs, and what
the new perspective
is for the future.
Of course, this presentation
reflects my personal
view, not the view of
the WHO or
any of the organizations
I'm collaborating with.
1:01
The Global Report
2023 underlines
three very important aspects
compared to the past years.
The first one is that there was
a major global recovery in the
number of people diagnosed with TB
and treated in 2022 after two
years of COVID-related disruption.
This started to
reverse or moderate
the damaging impact of
the pandemic on the diagnosis
and treatment of people
with tuberculosis.
However, tuberculosis
remains the world's
second leading cause
of death from a single
infectious agent in 2022.